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Better care for babies: the added value of a
modified reverse syphilis testing algorithm
for the treatment of congenital syphilis in a
maternity Hospital in Central African
Republic
Oluwakemi F. Ogundipe1* , Rafael Van den Bergh1, Behounde Thierry2, Kudakwashe C. Takarinda3,4,6,
Claude P. Muller5, Collins Timire3,4,6, Severine Caluwaerts1, Pascale Chaillet1 and Isabel Zuniga1
Abstract
Background: In high syphilis prevalence settings, the syphilis testing and treatment strategy for mothers and
newborns must be tailored to balance the risk of over treatment against the risk of missing infants at high-
risk for congenital syphilis. Adding a non-treponemal test (Rapid Plasma Reagin - RPR) to a routine rapid
treponemal test (SD Bioline Syphilis 3.0) for women giving birth can help distinguish between neonates at
high and low-risk for congenital syphilis to tailor their treatment. Treatment for neonates born to RPR-reactive
mothers (high-risk) is 10 days of intravenous penicillin, while one dose of intramuscular penicillin is sufficient
for those born to RPR non-reactive mothers (low-risk). This strategy was adopted in March 2017 in a
Médecins Sans Frontières supported hospital in Bangui, Central African Republic. This study examined the
operational consequences of this algorithm on the treatment of newborns.
Methods: The study was a retrospective cohort study. Routine programmatic data were analysed. Descriptive
statistical analysis was done. Total antibiotic days, hospitalization days and estimated costs were compared to
scenarios without RPR testing and another where syphilis treatment was the sole reason for hospitalization.
Results: Of 202 babies born to SD Bioline positive mothers 89 (44%) and 111(55%) were RPR-reactive and non-reactive
respectively (2 were unrecorded) of whom 80% and 88% of the neonates received appropriate antibiotic treatment
respectively. Neonates born to RPR non-reactive mothers were 80% less likely to have sepsis [Relative risk (RR) = 0.20;
95% Confidence interval (CI) = 0.04–0.92] and 9% more likely to be discharged [RR = 1.09; 95% CI = 1.00–1.18]
compared to those of RPR-reactive mothers. There was a 52%, and 49% reduction in antibiotic and hospitalization days
respectively compared to a scenario with SD-Bioline testing only. Total hospitalization costs were also 52% lower
compared to a scenario without RPR testing.
Conclusions: This testing strategy can help identify infants at high and low risk for congenital syphilis and treat them
accordingly at substantial cost savings. It is especially appropriate for settings with high syphilis endemicity, limited
resources and overcrowded maternities. The babies additionally benefit from lower risks of exposure to unnecessary
antibiotics and nosocomial infections.
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Background
Syphilis is a bacterial infection caused by Treponema
pallidum. The prevalence of syphilis in pregnant women
is < 1% worldwide and 1.5% in the African region; Africa
carries 57% of the global burden of syphilis infection in
pregnancy [1]. During pregnancy, mother-to-child trans-
mission (MTCT) rates for active syphilis could range
from 60 to 100% [2]. Adverse outcomes occur in 52% of
pregnancies with probable active syphilis, and include
perinatal deaths neonatal deaths and prematurity or low
birth weight [1, 3, 4]. The neonatal mortality rate from
congenital syphilis can be as high as 10% and long-term
morbidity can also be substantial [3]. The African region
also accounts for 61% of the global burden of syphilis-as-
sociated adverse outcomes in children [1]. These adverse
outcomes are preventable if adapted diagnostic and
treatment algorithms are implemented.
The two types of tests that are typically available for
syphilis testing are treponemal and non-treponemal
tests. The treponemal tests, while specific, do not distin-
guish between past and active infection. The non-trepo-
nemal tests can have false positives due to other
spirochetal and viral infections, malaria, TB and other
conditions [2, 5]. Individually, neither type of test can
definitively diagnose active syphilis, so a combination of
both tests [3, 6] is typically recommended to properly es-
tablish a diagnosis. Probable active syphilis is thus
defined as both a non-treponemal and treponemal test
being positive. The classic testing strategy is a screening
test with a non-treponemal test followed by a confirma-
tory test with a treponemal test. Depending on these re-
sults further testing with a non-treponemal test may be
required based on the results of the first two tests. The
reverse testing strategy starts with a treponemal test
followed by a confirmatory non-treponemal test with
further treponemal testing based on the results of the
first two tests.
The diagnosis of congenital syphilis is particularly dif-
ficult because testing algorithms for delivering women
using these two types of tests cannot definitively confirm
MTCT [5]. Babies born to mothers with syphilis (diag-
nosed by either test type) are classified into different risk
categories, and additional testing of the neonate is rec-
ommended in some guidelines [2, 6]. Neonatal treatment
is a 10-day course of intravenous penicillin when the risk
for congenital syphilis is high or a single intramuscular
injection of penicillin when the risk is low. Neonatal risk
depends on the testing algorithm, maternal history and
previous maternal treatment for syphilis [2, 3, 6].
In high-prevalence and low-resource settings (which
often coincide) where there is a higher chance of mater-
nal past infection, which carries a low-risk of congenital
syphilis [5], the syphilis testing strategy needs to be tai-
lored. In settings where syphilis testing is not guaranteed
during antenatal care (ANC), syphilis testing at the time
of delivery is warranted. It must balance the risk of over
treatment, which can lead to congested neonatal wards,
and unnecessary exposure to antibiotics, with the risk of
missing infants that are at a higher risk for congenital
syphilis. One such setting is the Central African Republic
(CAR), which has the second highest neonatal mortality in
the world at 41.5 per 1000 live births [7, 8]. The preva-
lence of syphilis in pregnancy is estimated between 4.7 to
10% [8, 9]. Along with 11 other countries, CAR has been
targeted by the World Health Organization (WHO) for
intensified support for the elimination of MTCT of syph-
ilis [9]. Other syphilis testing strategies such as paired sera
testing during pregnancy are not part of the testing
algorithm for syphilis in CAR. Instead, single Venereal
Disease research laboratory (VDRL) or Treponema palli-
dum hemagglutination assay (TPHA) are recommended,
because ANC attendance, after the initial visit, is unreli-
able [10, 11]. Polymerase chain reaction (PCR) testing is
also not available in CAR, even at the highest level of care
at the district hospitals [10].
In the Medecins Sans Frontieres (MSF) supported
Castors Maternity Hospital in CAR, maternal syphilis was
diagnosed using the SD Bioline Syphilis 3.0- Standard
Diagnostics (treponemal) test until March of 2017. Since
reliable maternal treatment information was not available,
it was not possible to differentiate high and low risk neo-
nates. As a result all infants born to SD Bioline positive
mothers were treated for 10-days with IV penicillin. This
potentially resulted in over-treatment as neonates born to
mothers with past infection were not excluded. In March
of 2017, the Rapid Plasma Reagin (RPR) (non-treponemal)
test was added as a confirmatory test to distinguish be-
tween past and probable active infection. The mothers
and babies were treated based on the results of the two
tests in this modified reverse testing algorithm. This
allowed the option of giving infants at low-risk for con-
genital syphilis a single dose of penicillin instead of a 10-
day treatment course [2, 6]. This change was expected to
reduce unnecessary antibiotic exposure and to reduce the
number of infants staying for 10 days in the typically
crowded neonatal ward.
Several studies have investigated the cost-effectiveness
of syphilis testing in avoiding adverse outcomes for both
the mothers and infants, while others have looked at the
effect of different maternal testing strategies on the clin-
ical management of mothers and the elimination of
MTCT in various settings [12–16]. These analyses are
based on theoretical models and projections [12–14].
Yet, no study has fully explored the operational benefits
of using this type of testing/treatment algorithm (in this
case: treponemal test + non-treponemal test) for the ini-
tial hospital care of newborns. We therefore assessed the
effect of such an algorithm on hospitalization days and
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associated costs for neonatal patients in this high-preva-
lence setting.
Methods
Aim
We set out to determine among all delivering mothers at
Castors Comprehensive Emergency Obstetric and New-
born Care Centre (CEmONC) from 23 March 2017–11
February 2018: i) the number and proportion of mothers
testing positive for syphilis infection using SD Bioline test
and their RPR results ii) the proportion of neonates receiv-
ing appropriate antibiotic therapy based on the maternal
RPR results iii) their hospitalization outcomes iv) actual
antibiotic and hospitalization days by treatment regimen
and v) treatment regimen-related health service costs.
Study design
Retrospective analytical cohort study using routinely col-
lected programme data.
General setting
CAR is located in central Africa. It has an estimated
population of 4.9 million [17]. Since 2013, there have
been recurrent internal conflicts leading to large popula-
tion displacements in and around Bangui, the capital
city. In May 2015 there was a peace agreement that was
signed by 9 of the 10 then existing militia groups. Never-
theless, armed conflicts continue intermittently. Cur-
rently 14 of the 17 prefectures of the country are under
the control of armed groups that limit free movement
throughout most of the country [18].
Specific setting
Bangui has an estimated population of 851,000 [18, 19]
and is divided into 8 zones. The study setting, Castors Ma-
ternity Hospital is located in the most densely populated
5th zone. This hospital has been supported since June
2014 by MSF Operational Centre Brussels, an inter-
national non-governmental organization providing hu-
manitarian aid and free medical assistance.
At Castors, MSF initially opened a Basic Emergency
Obstetric and Newborn Care centre (BEmONC) but
due to the patient needs it evolved into a CEmONC
with management of obstetrical complications and
neonatal services, comprised of kangaroo mother care
and a neonatal intensive care unit, providing care for
babies born in this facility. MSF does not provide or
support ante-natal care consultations in this setting.
In the last 3 years, bed occupancy rates have exceeded
the capacity of the structure with both women and
newborns being cared for in crowded facilities that
challenge adequate infection prevention and control
measures. Neonatal admissions for a 10-day course of
IV penicillin for risk of congenital syphilis contribute
to this congestion.
Syphilis testing and treatment
Pregnant women delivering in Castors Maternity Hos-
pital were tested for syphilis at the time of or after
delivery. Reliable information about prior syphilis in-
fection could not usually be obtained. Any history of
syphilis infection and/or treatment was solely based
on self-reporting at the time of the delivery as women
did not typically have an accessible patient file with
this information. In March 2017 a new algorithm was
introduced for testing mothers and treating newborns
delivered at Castors with the introduction of Rapid
Plasma Reagin (RPR) as a non-treponemal screening
test.
Under this new algorithm, high risk of congenital
syphilis was defined as a maternal RPR titre equal or
greater than 1:4, or evidence of maternal re-infection
(e.g., a chancre on physical examination), or a neonatal
physical examination consistent with congenital syphilis
(see Table 1). Low risk of congenital syphilis was defined
as a maternal titre of 1:2 without any evidence of mater-
nal re-infection and a newborn exam that was not indi-
cative of congenital syphilis. Neonatal RPR testing,
neonatal cerebrospinal fluid examination and additional
tests such as complete blood counts and bone radio-
graphs were not routinely done.
The algorithms used for testing and treating neo-
nates based on maternal syphilis tests are shown in
Fig. 1. The new testing algorithm was a modified ver-
sion of the reverse testing algorithm where no further
treponemal testing of the mother or the neonate was
done after the confirmatory non-treponemal test. The
delivering mothers who were positive for syphilis by
the SD Bioline Syphilis 3.0 test were treated with 3
Table 1 Clinical features of early congenital syphilis
Hepatosplenomegaly.
Jaundice.
Nasal discharge (snuffles).
Lymphadenopathy.
Maculopapular rash.
Skeletal abnormalities (Osteochondritis, Periostitis).
Pneumonia.
Pseudoparalysis.
Oedema.
Mucocutaneous lesions.
Hemolytic anaemia.
Thrombocytopenia.
All clinical features above are present at birth or within 4–8 weeks after birth
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doses of intramuscular penicillin weekly regardless of
RPR result, unless there was evidence that the mother
was treated before and there was no suspicion of re-
cent re-infection.
The SD Bioline Syphilis 3.0 (Standard Diagnostics)
is a solid phase immunochromatographic assay for
the qualitative detection of antibodies of all isotypes
(IgG, IgM, IgA) against Treponema pallidum (TP)
with a manufacturer-reported sensitivity and specifi-
city of 99.3 and 99.5% respectively. The RPR (ELI-
Tech group, France) is a serologic cardiolipid and
non-treponemal test for the rapid diagnosis of syphilis
with > 99% sensitivity and specificity according to the
manufacturer. Both tests are done in the Castors la-
boratory, a relatively well-stocked laboratory with the
capacity to perform serological tests.
Study population
All mothers who were positive for syphilis by SD Bioline
test and their live newborns that were tested and treated
for syphilis from March 23rd 2017 to February 11th 2018.
Data variables, sources of data and data collection
methods
Variables collected included aggregate number of live
births during the study period, date and result of RPR
tests for mothers who were SD Bioline positive, ma-
ternal age, and neonatal information on date of birth,
birthweight, gender, admission date, number of days
of penicillin received, exit diagnoses, exit date and
disposition. Data on unit costs of the RPR test and
penicillin as well as hospitalization costs were also
obtained. Antibiotic days were defined as the aggre-
gate number of days for which any amount of a
specific antibiotic was administered to a patient and docu-
mented in the medical records. Hospital days were defined
as the total number of days a patient stayed in hospital.
Admissions for < 24 h were counted as one hospital day.
Maternal and neonatal data were abstracted from
project monthly situation reports and annual and tri-
mestral reports, laboratory records, neonatal register and
neonatal patient files. Only data on the mother’s age
were available from these sources. No other sociodemo-
graphic data (e.g. Profession, parity, number of living
children, and psychosocial risk factors) were available.
Costs of daily maternal room and board costs were ob-
tained from the project supply manager whilst program
data on antibiotic and medical test costs were obtained
from the project pharmacist. Data were collected during
a routine support visit in June 2018.
Patient chart numbers were collected in place of
names during data abstraction and merged to sequential
numbers to create unique identifiers. The data were col-
lected on paper collection forms and afterwards double
entry was done into an EpiData database (Version 3.1
EpiData Association, Odense, Denmark).
Analysis and statistics
Data analysis was done using EpiData Analysis
V2.2.2.186 (EpiData Association, Odense, Denmark) and
Stata MP 15.1 (StataCorp, College Station, Texas 77845
USA). Means (standard deviations) were calculated for
normally distributed continuous data and medians
(interquartile ranges) for skewed continuous data whilst
numbers and proportions were calculated for categorical
data. Differences between groups were assessed using
Pearson’s X2 (Chi-square) test, and alternatively the Fish-
er’s exact test if assumptions for the Chi-square test were
Fig. 1 Algorithm for treating neonates with risk of congenital syphilis before and after March 2017. RPR = Rapid plasma reagin test. SD Bioline
and RPR tests are done on the mothers and the infants are treated based on the results for risk of congenital syphilis at MSF Castors
Maternity Hospital
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not met. The level of significance was set at p ≤ 0.05 and
95% confidence intervals (CI) were used throughout.
For the health cost analysis, actual calculated costs
were compared to counterfactual theoretical models de-
scribed in Table 2 below. The formulas used for these
calculations are also shown in Table 2. The costs of
other treatments unrelated to the diagnosis of risk of
congenital syphilis were not included in the cost calcula-
tions. The 8 cases where the length of stay or RPR titre
or number of penicillin days was unknown were ex-
cluded from this calculation. A conversion factor of
655.08 CFA to 1 euro was used for calculations. The es-
timated cost per day of hospital stay took into account
food and a hygiene kit (soap, cloth, mosquito net) pro-
vided to each mother (10.27 Euros). Staff time was not
included in the cost calculation. The costs of an individ-
ual RPR test unit and the cost of a unit of penicillin were
constant values obtained from the MSF catalogue.
Results
The number of total live births and the live births to
mothers who were SD Bioline positive and subsequently
RPR tested is shown in Fig. 2. Of the 8,485 live births at
MSF Castors Maternity hospital during the study period,
202 (2.4%) were born to SD Bioline positive mothers of
whom 200 (99%) had recorded RPR test results. The
breakdown of newborns enrolled in the study shows that
80% of babies of RPR reactive mothers and 88% of
neonates of RPR non-reactive mothers received
appropriate treatment (p = 0.13). The neonates who re-
ceived inappropriate treatments were those who did not
receive the correct penicillin treatment based on mater-
nal RPR results. Among the 17 babies born to RPR re-
active mothers who received inappropriate treatment, 7
(41%) were discharged earlier than ten days while the
other 10 had treatments interrupted by death, transfer
or leaving against medical advice. No treatment was dis-
continued due to an allergic reaction. On the other hand
all of the 13 babies who received inappropriate treat-
ment among those born to RPR non-reactive mothers
were discharged. All of these 13 babies received at least
one day of treatment with penicillin.
Selected demographic characteristics of the neonates
and maternal age are shown in Table 3. The average
length of stay for babies born to RPR reactive mothers
was 8.9 +/− 2.9 days, while the average length of stay for
babies born to RPR non-reactive mothers was 2.13 +/−
4.9 days (p < 0.001).
Table 4 shows the additional diagnoses and outcomes
of neonates born to RPR reactive and non-reactive
mothers in the study period. Comparable proportions of
babies born to RPR reactive and RPR non-reactive
mothers had other discharge diagnoses (27% versus 26%,
p = 0.87). The babies born to mothers who were RPR
non-reactive were significantly less likely to have sepsis
[RR = 0.20; 95% CI = 0.04–0.92] and were more likely to
be discharged [RR = 1.09; 95% CI = 1.00–1.18, p = 0.049]
than babies born to RPR reactive mothers. The mortality
rate among all patients was 1.5%. Of the patients whose
mothers were RPR reactive, there were 10 patients who
were not discharged but instead were transferred, died
or left against medical advice. These patients contributed
a total of 29 days instead of the predicted total of 100
days in hospital.
For the subsequent analyses two counterfactual sce-
narios were used. In scenario A the theoretical antibiotic
treatment was based solely on the SD Bioline test (irre-
spective of the RPR result), while in scenario B patients
born to RPR reactive mothers would receive 10 days of
treatment and those born to RPR non-reactive mothers
would receive 1 day of treatment, and no other factors
affect treatment or length of stay. In scenario B, treat-
ment for risk of congenital syphilis was considered to be
the only condition for which the child was admitted.
The actual total number of antibiotic and hospitalization
days for neonates included in the study period as com-
pared to the two counterfactual scenarios is shown below
(Fig. 3). At Castors, the total number of days when the ne-
onates were receiving penicillin for syphilis therapy
accounted for 94% of the total hospitalization days. There
was a 52% reduction in the total number of antibiotic days
and a 49% reduction in the total number of hospitalization
days when compared to scenario A. The actual total
Table 2 Estimation of Syphilis Treatment Associated Cost
(Euros) for Babies Treated for Risk of Congenital Syphilis
Cost Calculations (Euros)a
Scenario A: Assumes that all neonatal patients were treated for 10 days
with penicillin (PCN) irrespective of maternal RPR results.
Syphilis treatment associated cost of hospital stay for each
patient = (Cost of unit of PCN [3.07] × 23 doses) + (Cost of hospital day
[10.27] × 10 days).
Scenario B: Assumes that all mothers were tested with both SD Bioline
and RPR. Patients born to RPR reactive mothers were treated for 10 days
with IV penicillin while patients born to RPR non-reactive mothers were
treated with a single dose of penicillin.
RPR reactive: Syphilis treatment associated cost of hospital stay = (Cost of
unit of PCN [3.07] × 23 doses) + (Cost of hospital day [10.27] × 10 days) +
Cost of RPR test unit [0.72].
RPR non-reactive: Syphilis treatment associated cost of hospital stay =
Cost of unit of PCN [3.07] + Cost of hospital day [10.27] + Cost of RPR
test unit [0.72].
Actual situation:
Syphilis treatment associated cost of hospital stay for each
patient = (Cost of unit of PCN [3.07] × # of doses of PCN) + (Cost of
hospital day [10.27] × # of hospital days) + (Cost of RPR test unit [0.72]).
PCN Penicillin, RPR Rapid plasma reagin
Legend: aAll costs are in Euros. Estimated and actual costs at MSF Castors
Maternity Hospital, March 2017 to February 2018
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number of antibiotic days was 3% less than the theoretical
antibiotic days predicted by scenario B.
Figures 4 and 5 compare the total cost for all patients
included in the study and the theoretical costs in scenar-
ios A and B described above. Hospitalization days and
number of doses of antibiotics were used in this calcula-
tion. The analysis showed that the total cost of
hospitalization during the study period was 52% lower
than it would have been without RPR testing (scenario
A). Meanwhile there was no significant difference be-
tween the total theoretical cost (scenario B) and the total
actual cost (Actual cost was 1.3% less).
In scenario B, where cost was only dependent on ma-
ternal RPR results, neonates born to RPR non-reactive
mothers should only account for 9% of the total cost,
while at Castors these neonates account for 21% of the
total cost (Fig. 4) due to additional hospitalization days
for other causes.
Discussion
In this study the effect on newborns of the introduction
of a more comprehensive testing/ treatment algorithm
for maternal syphilis was examined. This algorithm was
a step up in laboratory testing and added some complex-
ity to care for infants at risk for syphilis. Nevertheless,
our results showed that its implementation had added
value since all but 2 SD Bioline positive mothers failed
to have recorded confirmatory RPR tests, and most of
the infants were treated accordingly. Among the babies
born to RPR reactive mothers, the percentage of babies
treated adequately could have potentially been even
higher than 80% if outcomes of transfer and leaving
against medical advice were excluded. This demonstrates
that this algorithm is suitable for high-prevalence set-
tings that have the minimal laboratory capacity to pre-
pare serum and have minimal human and monetary
resources.
The frequency of cases with probable active infection
was 1%, which is considerably less than the 4.7% most
recently reported for CAR [8], and less also than the
4.4% estimate for the general population in Bangui from
2013 [20]. These differences may be due to the popula-
tion shifts that occurred in Bangui since the conflicts
(which also began in 2013). It may also be due to the lo-
cation of the maternity in Bangui, an urban centre, with
potentially increased access to health services when
compared to other parts of the country. A study com-
paring syphilis rates among pregnant women in urban
and rural CAR showed four-fold higher odds of having
probable active syphilis in rural areas in CAR [21].
Fig. 2 Pattern of deliveries and syphilis testing of mothers and treatment of their infants. Legend: SD Bioline and RPR tests are done on the
mothers and the infants are treated based on the results at MSF Castors Maternity Hospital from March 2017 to February 2018.a RPR = Rapid
plasma reagin testb RPR reactive = titre > 1:4c RPR non-reactive = titre of 1:2. MSF = Médecins Sans Frontières
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It is estimated that 16% of babies born to mothers with
untreated syphilis would have congenital syphilis [22],
with half of these babies showing clinical signs of low
birth weight/prematurity and skeletal malformations
[22]. We found neither clinical signs of neonatal syphilis
(no diagnoses of congenital malformations), nor any as-
sociation with prematurity/low birth weight in this study
other than the increased likelihood of the babies born to
RPR reactive mothers of being diagnosed with sepsis.
As expected the dual testing algorithm considerably
reduced the number of infants requiring a 10-day treat-
ment and halved the antibiotic and hospitalization days.
The results also demonstrated that despite other clinical
diagnoses and reasons for continuing hospital care, the
antibiotic days and hospitalization days saved were close
to what was predicted when risk of syphilis was the only
diagnosis for which these babies were admitted. The ac-
tual total number of antibiotic days was less by 3% than
the theoretical total antibiotic days predicted mostly due
to patients who were transferred, left against medical ad-
vice or died before receiving the full course of treatment.
Notably 6 of the 17 babies born to RPR reactive
mothers who did not receive adequate penicillin therapy
left against medical advice. It is possible that a higher
number of babies would have left early without receiving
adequate treatment if this algorithm was not in place
and all babies had to be treated with 10 days of penicil-
lin. Another notable finding was that 8% (7/89) of babies
born to RPR reactive mothers were treated inappropri-
ately. This finding will be relayed back to Castors to
reinforce their screening algorithm to assure that no fur-
ther babies at high risk for congenital syphilis are dis-
charged with inappropriate treatment. The 12% of
babies born to RPR non-reactive mothers who were
treated inappropriately is less concerning as all of them
received at least one day of penicillin therapy, and a sin-
gle (intramuscular) dose of penicillin is as effective as a
classic 10 days of therapy for babies whose risk of syph-
ilis is low [22]. The babies at low risk for syphilis bene-
fited from treatment according to this algorithm as they
had reduced exposure to unnecessary antibiotics.
The reduced antibiotic and hospital days also resulted
in considerable cost savings of 52% because the RPR test
is inexpensive. In other settings with a high prevalence
of syphilis e.g. South Sudan, Mali [8], where funding and
human resources are scarce, these cost savings could
lead to improved quality of care and less crowded spaces
Table 3 Demographic characteristics of neonates and their
mothers stratified by Maternal RPR result
Demographic
Characteristics
RPRa Reactiveb RPRa Non-reactivec p-
valueN = 89 (%) N=111 (%)
Total 89 (100) 111 (100)
Birth weight (g) NS
<1500 0 (0) 2 (2)
1500-2499 10 (11) 10 (9)
> 2500 79 (89) 99 (89)
Sex NS
Male 41 (46) 55 (50)
Female 46 (52) 56 (50)
Not recorded 2 (2) 0 (0)
Maternal age
15-24 28 (31) 48 (43) NS
25-34 39 (44) 37 (33) NS
35-44 16 (18) 15 (14) NS
> 45 0 (0) 1 (1) NS*
Not recorded 6 (7) 10 (9)
All neonates with risk of congenital syphilis MSF Castors Maternity Hospital
from March 2017 to February 2018
X2 test used for all comparisons except where indicated as (*) Fisher’s
exact test
aRPR Rapid plasma reagin testb RPR reactive = titre > 1:4c RPR non-reactive =
titre of 1:2
NS Non-significant
Table 4 Diagnoses and hospitalization outcomes of newborns
treated for risk of congenital syphilis
RPRa
Reactiveb
RPRa Non-
reactivec
p-
value
N=89 (%) N=111 (%)
Discharge Diagnosesd
None 65 (73) 82 (74) NS
Sepsis 8 (7) 2 (2) 0.02*
Perinatal asphyxia 4 (4) 7 (8) NS*
Premature/low birth weight 3 (3) 3 (3) NS*
Antibiotic prophylaxis (well baby)e 9 (8) 15 (17) NS
HIV Exposure 4 (4) 9 (10) NS
Number of diagnoses
None 65 (73) 82 (74) NS
One diagnosis 20 (22) 22 (20) NS
Two diagnoses 4 (5) 7 (6) NS*
Disposition
Discharged 79 (89) 107 (96) 0.05
Transferred 2 (2) 0 (0) NS*
Dead 2 (2) 1 (1) NS*
Left against medical advice 6 (7) 3 (3) NS*
X2 test used for all comparisons except where indicated as (*) Fisher’s
exact test
Neonatal treatment was based on Maternal RPR Results at MSF Castors
Maternity Hospital from March 2017 to February 2018
aRPR Rapid plasma reagin test b RPR reactive = titre > 1:4c RPR non-reactive =
titre of 1:2
dSum of n for discharge diagnoses is not equal to 100% as patients can
present with more than one diagnosis
NS = Not significant
eAntibiotic prophylaxis = infants who are treated for a minimum of 48 h of
antibiotics based on maternal and birth risk factors but who are
otherwise well
Ogundipe et al. BMC Pediatrics          (2019) 19:284 Page 7 of 10
for mothers and babies. This would allow more mothers
and babies to be admitted and treated.
The reduction in hospitalization days had an added
benefit of avoiding other risks of hospitalization such as
nosocomial infections, medication errors etc. Castors
Neonatal Ward had a nosocomial outbreak of extended
spectrum beta lactamase (ESBL) Klebsiella species dur-
ing the observation period. Babies who spent only one
day hospitalized for treatment for risk of syphilis instead
of ten reduced their risk of nosocomial infection. With
the rise of ESBL and other resistant forms of neonatal
sepsis in low and middle-income countries [23] an algo-
rithm like this will contribute to reducing the risk of
nosocomial infections with resistant pathogens in the
hospitalized neonatal population. This effect would be
much greater in the low income countries that have low
ANC coverage and limited antenatal screening and treat-
ment for syphilis [11].
This study had distinct strengths. First, the high
prevalence of syphilis and the high risk of congenital
syphilis in this population were important to demon-
strate the substantial cost benefit of introducing the
RPR test. Second, all patients at risk for congenital
syphilis were included hence the findings are wholly
representative and relatable to other routine pro-
grammes in similar settings.
Limitations include that the study was conducted in
an urban setting and may hence not be generalizable to
other parts of the country. Another limitation is that the
study did not look at neonatal outcomes past the initial
Fig. 3 Actual and theoretical antibiotic and hospital days saved for neonates at MSF Castors Maternity Hospital. Legend: RPR = Rapid plasma
reagin. Antibiotic days = Aggregate number of days for which any amount of a specific antibiotic is administered to a patient and documented in
the medical record (adapted from CDC definition). Hospital days = The total number of days a patient stays in hospital. Scenario A: Assumes that
all patients were treated for 10 days with penicillin irrespective of maternal RPR results. Scenario B: Assumes that all mothers were tested with
both SD Bioline and RPR. Patients born to RPR reactive mothers were treated for 10 days with IV penicillin while patients born to RPR non-reactive
mothers were treated with a single dose of penicillin.MSF Castors: Actual antibiotic and hospital days for patients born to RPR reactive and RPR
non-reactive mothers at MSF Castors from March 2017 to February 2018
Fig. 4 Health Cost Comparisons Between Actual and Theoretical Situations for Neonates at Risk for Congenital Syphilis. Legend: RPR = Rapid
plasma reagin. For descriptions of Scenarios A and B see Legend of Fig. 4. MSF Castors: Actual antibiotic and hospital days for patients born to
RPR reactive and RPR non-reactive mothers at MSF Castors from March 2017 to February 2018
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hospitalization period so late symptoms of congenital
syphilis would have been missed. This subject warrants
further investigation in future studies. However, since all
babies were treated with at least one dose of penicillin,
the risk of late onset congenital syphilis is low [22].
The cost and health care benefits of antenatal syphilis
screening is well known [24]. Several studies have also
described the benefits of using various syphilis testing al-
gorithms during antenatal care in different contexts [25].
There are no studies that have explored the operational
costs and benefits for the initial hospital care of new-
borns of using this type of treatment algorithm.
This study has some important implications. The cost
savings are expected to vary as a function of the percent-
age of delivering women who are both SD Bioline positive
and RPR reactive. The higher the percentage of women
with past resolved infection the more costs saved with this
algorithm. Ideally the risk of congenital syphilis is most
greatly reduced by reinforcing antenatal testing and treat-
ment of syphilis; nevertheless implementation of this test-
ing and treatment strategy for infants at risk for syphilis
will have several benefits. It could greatly decongest neo-
natal wards thus freeing up beds for other neonates who
may need them and prevent overtreatment and the associ-
ated risks for babies born to mothers with syphilis.
Conclusions
In conclusion, congenital syphilis continues to be a signifi-
cant morbidity requiring treatment among neonatal popu-
lations. In sites where there is high prevalence of syphilis
the testing and treatment strategy should appropriately
identify and treat those infants at risk for congenital
syphilis. This study demonstrates that an algorithm like
the one implemented in Castors can help distinguish be-
tween infants at high and low risk and treat them accord-
ingly in a low-resource setting. The implementation of an
algorithm like this also has significant benefits for the in-
fants in reducing unnecessary risks associated with anti-
biotic use and hospitalization and for the hospitals in
rationalizing expenditure in health care provision.
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